Results 311 to 320 of about 14,301,803 (394)

Want to be fit? Start with your mind! The role of the placebo effect in physical fitness in children: a preliminary systematic review and meta-analysis. [PDF]

Int J Obes (Lond)
Żegleń M, Kryst Ł, Bąbel P.
europepmc   +1 more source

Placebo effect of information

, 2001
Rihei Fujimoto
openalex   +2 more sources

Population Pharmacokinetic and Exposure‐Response Analysis of the Cognitive Effects of TAK‐071 in Participants With Parkinson Disease and Cognitive Impairment

Clinical Pharmacology in Drug Development, EarlyView.
Abstract TAK‐071 is a novel muscarinic M1 positive allosteric modulator under investigation for the treatment of cognitive impairment and falls associated with Parkinson disease (PD). This study evaluated population pharmacokinetics of TAK‐071 following single (1‐160 mg) and multiple (3‐15 mg once daily) oral‐dose TAK‐071 in 112 healthy participants ...
Hongxia Jia, Axel Facius, Rachel Jennings, Yaming Hang, Jaya Padmanabhan, Niraj M. Shanbhag, Brian T. Harel, Arthur Simen, Wei Yin   +8 more
wiley   +1 more source

Prospective, randomized, crossover evaluation of the effect of propranolol, nadolol, and placebo on neurocardiogenic syncope recurrence and patients' well-being Panagiota Flevari, Efthimios G. Livanis, George N. Theodorakis, Elizas Zarvalis, Dimitrios T. Kremastinos. Onassis Cardiac Surgery Center, Athens, Greece

, 2001

openalex   +1 more source

Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Aripiprazole once‐monthly (AOM) is approved for the maintenance monotherapy treatment of bipolar I disorder (BP‐I) in adults. A previously developed population pharmacokinetic model was validated by applying it to data from patients diagnosed with BP‐I.
Xiaofeng Wang, Luann Phillips, Matthew Harlin, Karimah S. Bell Lynum, Frank Larsen, Pedro Such, Jessica Madera‐McDonough, Murat Yildirim, Ric M. Procyshyn, Craig Chepke, Julie Passarell   +10 more
wiley   +1 more source

The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials

, 2002
Graeme Jones, Jennifer P. Halbert, Maria Crotty, E. Michael Shanahan, Marijka Batterham, Michael Ahern   +5 more
openalex   +1 more source

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Endogenous oxytocin plays an important role in lactation, but its effectiveness as an exogenous galactagogue has been modest due to dose‐limiting side effects related to off‐target effects at the vasopressin V2 receptor. Merotocin (FE 202767) is a short‐acting peptidic oxytocin receptor agonist with the potential to aid mothers experiencing ...
Yu Bagger, Carina Holmqvist, Daniël M. Jonker, Bjarke M. Klein, Lorien E. Urban   +4 more
wiley   +1 more source

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi‐Keung Chen, Huixia Zhang   +11 more
wiley   +1 more source

The Effect of Midazolam on Stress Levels During Simulated Emergency Medical Service Transport: A Placebo-Controlled, Dose-Response Study

, 2002
Volker Dörges, Volker Wenzel, Susanne Dix, Alexander Kühl, Thomas Schumann, Michael Hüppe, H. Iven, Klaus Gerlach   +7 more
openalex   +1 more source

Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a Phase 2, randomized, double‐blind, placebo‐controlled trial. In total, 272 participants were randomized 3:1 to a single intravenous dose of 600 mg AZD7442 or placebo and
Jing Zhang, Huixia Zhang, Yajuan Zhang, Shuyuan Liu, Xiaoyun Ge, Haiyue Zhang, Yunfei Li, Cecil Chi‐Keung Chen, Oleg Stepanov, Weifeng Tang, Wenhong Zhang   +10 more
wiley   +1 more source